Skip to content

Contribution of the Pharmacological Profile of the A2A Receptor to Adenosine in the Diagnosis of Myocardial Ischemia

Contribution of the Pharmacological Profile of the A2A Receptor to Adenosine in the Diagnosis of Myocardial Ischemia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04640844
Acronym
RIMACI
Enrollment
170
Registered
2020-11-23
Start date
2021-01-25
Completion date
2023-06-30
Last updated
2021-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Coronary Artery Disease

Brief summary

The chronic coronary artery disease could be detected by a drop in the expression of A2A receptors to adenosine, while high values of the KD / EC50 ratio are a sign of coronary ischemia. Knowing the number of A2A receptors in circulating lymphocytes could allow detection of coronary artery disease and evaluating the functionality of A2A receptors in circulating lymphocytes could allow quantification of myocardial ischemia. Thus, a simple and unique blood sample would quickly detect patients with life-threatening coronary ischemia. This would avoid prolonged hospitalizations and costly non-invasive tests (stress echocardiography, myocardial scintigraphy) in patients without coronary artery disease.

Detailed description

The main objective of this study is to evaluate the discriminating capacities of A2A adenosine receptors expression on the surface of circulating lymphocytes for the detection of coronary artery disease in patients hospitalized for surgery of the aorta and / or arteries of the lower limbs. The secondary objectives are: Assessment of the discriminating capacities of the functionality (KD / EC50) of A2A adenosine receptors on the surface of circulating lymphocytes, for the diagnosis of myocardial ischemia in patients hospitalized for surgery of the aorta and / or arteries of legs. Determinate the best threshold for discriminating patients with coronary artery disease and estimate the discriminating performance associated with this threshold. Determinate the best threshold for discriminating patients with myocardial ischemia and estimate the discriminating performance associated with this threshold.

Interventions

BIOLOGICALblood sample

measuring the expression and function of lymphocyte A2A receptors.

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients admitted for preoperative assessment of vascular surgery of the aorta and / or arteries of the lower limbs. * Adult person (age\> 18). * Affiliated with a social security scheme. * Signature of informed consent.

Exclusion criteria

* Patients with a history of coronary artery disease awaiting revascularization. * Hyperthyroidism, anemia (Hb \<13 g / dL). * Contraindication to the practice of coronary angiography, stress echocardiography or myocardial scintigraphy. * Unstable hemodynamic state or cardiogenic shock. * Adults protected under guardianship, curatorship or legal protection. * Pregnant or lactating women

Design outcomes

Primary

MeasureTime frameDescription
Dosage of adenosine24 MONTHSmeasuring the expression and function of lymphocyte A2A receptors.

Countries

France

Contacts

Primary ContactALAEXANDRA GIULIANI
alexandra.giuliani@ap-hm.fr0491382747

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026